Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01528046 : Metformin in Children With Relapsed or Refractory Solid Tumors
PhasePhase 1
AgesMin: 1 Year Max: 18 Years
Eligibility
Inclusion Criteria:

- Age: Patients must be > 1 year of age and = 18 years of age at time of initiation of
protocol therapy.

- Diagnosis: Patients have a histologically or radiographically confirmed relapsed or
refractory solid tumor or primary central nervous system (CNS) malignancy.

- Disease Status: Patients must have radiographically measurable disease.

- Therapeutic Options: Patients must have relapsed or refractory cancers for which there
is no known curative option or other available therapy proven to prolong survival with
an acceptable quality of life.

- Performance Level: Karnofsky = 50% for patients older than 16 years old, and Lansky =
50 for patients 1-16 years old.

- Prior Therapy: Patients may have received prior therapy including vincristine,
irinotecan, or temozolomide. Patients may not have previously been treated with
combination therapy of irinotecan and temozolomide.

- Patients must be fully recovered from the acute toxic effects of all prior
chemotherapy, immunotherapy, or radiotherapy prior to entering this study.

- Myelosuppressive chemotherapy: Patients must not have received myelosuppressive
chemotherapy within 3 weeks of starting protocol therapy, or a minimum of six
weeks must have elapsed since prior nitrosurea chemotherapy.

- Hematopoietic growth factor: At least 7 days must have elapsed since the last
administration of filgrastim, or 14 days since administration of pegfilgrastim.

- Biologic (anti-neoplastic agent): At least 7 must have elapsed since the last
administration of any biologic agent.

- Radiation therapy (XRT): At least 14 days since the last dose of local palliative
radiation therapy. Greater than 6 months must have elapsed since the last day of
treatment if given total body irradiation, craniospinal irradiation.

- Autologous or Allogenic Stem Cell Transplant: Complete resolution of graft versus
host disease and no current need for immunosuppressive medication. Greater than 3
months must have elapsed since engraftment and no longer requiring transfusion of
platelets or injection of colony stimulating factors.

- Organ Function Requirements

- Bone Marrow Function: Peripheral absolute neutrophil count (ANC) = 1000/µL;
Platelet count = 100,000/µL (no platelet transfusion within 7 days prior to
obtaining laboratory result); Hemoglobin = 8.0 gm/dL

- Adequate Renal Function: Creatinine clearance or glomerular filtration rate =
70ml/min/1.73m^2

- Adequate Liver Function: Total bilirubin = 1.5x upper limit of normal (ULN) for
age; alanine transaminase (ALT) = 5x ULN; Serum albumin = 2gm/dL

- Informed Consent: All patients = 18 years of age must sign a written informed consent.
For patients < 18 years old, the patient's parents or legal guardians must sign a
written informed consent, unless the patient is an emancipated minor. Childhood
Assent, when age appropriate as per institutional guidelines, should be signed by the
participating patient.

Exclusion Criteria:

- Significant organ dysfunction, not meeting inclusion criteria.

- Pregnancy or Breast-Feeding woman will not be entered on this study due to risks of
fetal and teratogenic adverse events as seen in animal/human studies.

- Concomitant Medications:

- Growth factor: Growth factors that support platelet or white cell number of
function must not have been administered within the past 7 days.

- Steroids: Patients with CNS tumors who have not been on a stable or decreasing
dose of dexamethasone for the past 7 days.

- Investigational Drugs: Patients who are currently receiving another
investigational drug.

- Anti-cancer Agents: Patients who are currently receiving other anti-cancer
agents.

- Medication Allergy: Allergy or intolerance to agents on this protocol:
vincristine, irinotecan, temozolomide, or metformin; Allergy to cephalosporins.

- Infection: Patients who have uncontrolled infection, positive blood cultures
within the past 48 hours, or receiving treatment for Clostridium difficile
infection.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT01528046      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740